Pfizer surged after striking a landmark agreement with the Trump administration to lower drug prices and expand U.S. production. Indexes advanced modestly, led by healthcare and industrial strength. Among large pharma peers, Johnson & Johnson (JNJ 2.05%) ended at $185.42, up 2.09%, while Eli Lilly and Co (LLY 5.02%) finished at $763.00, up 5.02%. The company will reduce many drug prices, particularly in Medicaid, by matching the lowest prices abroad and launching new medicines at parity. The deal also ties Pfizer to TrumpRx, a newly announced direct-to-consumer drug sales platform.